Of note, a multicenter, randomized, open-label, prospective, controlled, parallel-group study, called TRACK (The Treatment of Rheumatoid Arthritis and Comorbidities with Kineret), investigated whether IL-1 inhibition with anakinra, as compared with TNF inhibitors (e.g., etanercept, adalimumab, infliximab, certolizumab pegol, or golimumab), could lead to improvements in both metabolic and inflammatory parameters in patients with RA and T2D [176]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.